Case report: ALK D1225N missense mutation in lung adenocarcinoma responds to tyrosine kinase inhibitors

ALK gene missense mutations are conventionally considered non-driver without pathological significance, and therefore, there is a lack of effective target drugs against them. The standard treatment option for patients with chemotherapy or antiangiogenic agents, which usually results in unsatisfactory outcomes. Herein, we present the case patient metastatic lung adenocarcinoma harboring only mutation D1225N responding to two ALK-tyrosine kinase inhibitors (TKIs), namely, crizotinib ensartinib. Our highlights that non-small cell cancer (NSCLC) may benefit from ALK-TKIs, ALK-TKIs should be candidates further line treatment.